James W Mccollum Receives Stock Award at Lenz Therapeutics Inc (LENZ) — SEC Form 4, Jun 16, 2026
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| James W Mccollum CIK 0001200889 |
Director
|
James W Mccollum at Lenz Therapeutics Inc
Full insider history
Bought (12 mo)
$239,278
Sold (12 mo)
—
More from this insider at Lenz Therapeutics Inc
| 2025-11-10 | Buy | +$239,278 | View |
| 2025-06-11 | Award | — | View |
| 2024-05-14 | Buy | +$501,093 | View |
| 2024-03-25 | Award | — | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.63 | 2026-06-15 | A - Award/Grant | 22,100 A | $0.00 | 2036-06-15 | 22,100 Common Stock | Direct |
Footnotes (1)
- F1
- Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. Show more
Related filings at Lenz Therapeutics Inc
Institutional Holders
13F holders · Dec 31, 2023
63
institutional managers reporting a position
Largest by reported value
- Eco R1 Capital, Llc $22.4M
- Samsara Bio Capital, Llc $22.2M
- Tang Capital Management Llc $6.53M
5%+ Holders · 13D/G
6 filers
-
Fmr Llc 5.7%
-
Black Rock, Inc. 5.8%
-
Squarepoint Ops Llc 5.1%
Other insiders at Lenz Therapeutics Inc
GET /v1/forms/4/0001200889-26-000001
API docs
View Original SEC Filing